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The use ofmonoclonal antibodies produced bythe hybridoma technique has had a profound
impact on the biological and medical sciences. While the general technique for the production
ofmonoclonal antibodies is available from the numerous papers which report their use, there is
a need for a source which describes the procedure and its pitfalls in detail so that an in-
vestigator who decides to make hybridomas can do so quickly and easily. This guide provides
such a source.
INTRODUCTION
The use of monoclonal antibodies produced by the hybridoma technique
developed in 1975 by Kohler and Milstein [1] has led to a revolution in the biological
sciences. Monoclonal antibodies, unlike conventional antibodies, are directed
against a single antigenic determinant. Their unique specificity allows diverse
studies, which were previously difficult or impossible, to be done. These studies
range from the selective isolation and characterization of virtually any biological
substance to the functional analysis of such substances [2]. In the future,
monoclonal antibodies directed against unique tumor antigens promise a radical
development in cancer chemotherapy.
It is now rare to find an investigator who does not or could not use monoclonal
antibodies in some aspect of his research. Because of this demand for monoclonal
antibodies, many companies have recently begun selling such reagents and some
universities have set up "hybridoma facilities" in which investigators can have
hybridomas custom-made. However, the desired antibody may not be on the market
or a hybridoma facility may not be available, in which case it is most convenient to
produce one's own monoclonal antibodies.
Descriptions of the process for making hybridomas are available [3,4], but the
purpose ofthis guide is to provide complete step-by-step instructions for the produc-
tion of monoclonal antibodies using the hybridoma technology. Its use requires a
minimal degree of laboratory experience, including tissue culture experience, while
its content leaves few questions unanswered.
The basic process of making monoclonal antibodies is simple-a mouse is im-
munized with the appropriate antigen, spleen cells from the immunized animal,
many of which are producing antibody, are fused with murine myeloma cells using
387
*Predoctoral trainee of the Medical Scientist Training Program
Address reprint requests to: Ethan A. Lerner, Department of Pathology, Yale University School of
Medicine, 333 Cedar Street, New Haven, CT 06510
Copyright © 1981 by The Yale Journal of Biology and Medicine, Inc.
All rights of reproduction in any form reserved.ETHAN A. LERNER
polyethylene glycol, antibody from the resultant hybridomas secreted into the
culture medium screened for the activity of interest, and a permanent source of the
desired antibody is established (Fig. 1).
The general format of fusing mouse spleen and myeloma cells together has now
been expanded successfully to include fusions of primed rat spleen cells with mouse
or rat myeloma cells [5,6]. While there is an obvious desire to have human
monoclonal antibodies, fusions of human peripheral blood cells with mouse
myeloma cells rarely yield hybrids with a stable number of human chromosomes.
To solve this problem, one group of investigators has developed a human myeloma
line which has made it possible to make humani x human hybridomas [7]. The
techniques described in this paper are generally applicable to the above situations
with the exception that the culture media requirements for particular myeloma lines
may vary.
It should be noted that there are two additional methods of producing
monoclonal antibodies by non-standard hybridoma processes. The first, described
by Wright [8], uses diethyl pyrocarbonate to irreversibly inactivate sulphur-
containing enzymes in a given myeloma cell line. The damaged tumor cells are then
fused in a conventional manner with primed B cells and the active enzymes ofthe B
cells salvage the tumor cell to yield a functional hybridoma. The second method uses
the well-established technique of transforming human B cells with Epstein-Barr
virus and then selecting the transformed lines which secrete the antibody of interest
[9].
A word of caution: The production of hybridomas requires many months of
diligent effort. Most important, a simple and reliable screening assay to examine the
numerous culture supernatants for the desired antibody must be available before cell
fusion. The successful development of uniquely specific monoclonal antibodies is
well worth the effort.
PREPARATION OF HYBRIDOMAS
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FIG. 1. Pictorial description of the preparation of hybridomas.
388HOW TO MAKE A HYBRIDOMA
THEORY OF CELL FUSION
Hybridomas are formed by the fusion of a short-lived B cell, which secretes an-
tibodies of one specificity, with a long-lived myeloma cell. The product is a long-
lived cell line secreting antibodies of one specificity, hence monoclonal antibodies.
Because the parental myeloma cells have an unlimited life span in culture, it could
be difficult to pick the fused cells from the parents. To overcome this difficulty, a
method has been devised to select for only those cells which have successfully fused
[10]. The selective system we work with revolves around the enzyme hypozanthine-
guanine-phosphoribosyl transferase, HGPRT. This enzyme is responsible for the
purine salvage pathway in mammalian cells. These cells are also capable of syn-
thesizing purines de novo. Under most conditions both pathways probably operate
to a certain extent. If a cell lacks HGPRT, the salvage pathway is blocked and
purines must be manufactured from non-purine materials.
8-azaguanine is an antimetabolite which "looks enough" like the purine guanine to
enter some of the normal salvage pathways of guanine. 8-azaguanine is then incor-
porated into DNA, interfering with normal cell growth and leading to cell death.
Since 8-azaguanine must be "salvaged" and HGPRT is responsible for the salvage
pathway, any cell which lacks HGPRT activity cannot utilize 8-azaguanine and will
grow in its presence.
A selective system which operates on the same enzyme but in theopposite sense, in
that HGPRT+ cells are selected, is called HAT-hypoxanthine, aminopterin,
thymidine. Aminopterin is an antimetabolite that prevents de novo purine synthesis
and methylation of deoxyuridylate to form thymidylate. Hypoxanthine can serve as
a "salvageable purine" in the event aminopterin blocks de novo purine biosynthesis
while thymidine bypasses the necessity for the methylation of thymidylate. Thus, in
the presence of aminopterin, any cell with HGPRT activity will proliferate while
HGPRT- cells will die.
In the hybridoma system, the myeloma cells have been rendered resistant to
8-azaguanine and are susceptible to aminopterin, i.e., HGPRT-. The other fusion
partners are HGPRT' cells (normal B cells and other spleen cells). By fusing the cells
and growing them in HAT medium without azaguanine, we select for successfully
fused cells because the myeloma cells which constitute the proliferating line can only
grow if HGPRT activity is present, and this activity must be supplied by the
HGPRT+ B cell. The B cells are not killed in this media and live for a time, but will
not proliferate in culture.
The myeloma line best suited for mouse-mouse (and which works well for rat x
mouse) fusions is called SP 2/0 Ag 14 and is itself derived from a hybridoma [11].
The advantage of SP 2/0 over previously availablemyeloma lines is that SP 2/0 does
not synthesize any immunoglobulin components (unlike other myelomas), which
would intermix heavy and light immunoglobulin chains with those of the B cell. The
resultant antibodies from a fusion using SP 2/0 are truly homogeneous (Fig. 2).
IMMUNIZATION
The initial question about immunization is, "How pure must the antigen be?"
There is not an exact answer to such a question, as different antigens elicit highly
variable immune responses. The purer the antigen, the better the chance ofthe proper
antibodies being produced, but difficulty in obtaining a pure preparation should
never be a deterrent in an attempt to make hybridomas.
The second question is, "Which mouse strain should be used?" As the myeloma
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lines are all of BALB/c origin and ascites fluid from hybridomas is grown in mice
which must share BALB/c histocompatibility antigens, to prevent rejection of the
hybridoma tumor, BALB/c mice are the most convenient strain to immunize. There
are occasions when other strains may be better recipients of the antigen than
BALB/c mice. SJL mice typically make very vigorous immune responses and may
be better recipients than BALB/c for a particular antigen. If one is interested in ob-
taining monoclonal autoantibodies, a fusion would have to be done between the
BALB/c derived myeloma and spleen cells from the autoimmune strain. To grow
ascites antibody in these two instances, an F1 animal, where BALB/c is one parent
and a strain with an identical major histocompatibility type of the SJL or the
autoimmune animal is the other parent, would be needed.
There are two broad classes ofantigens to which investigators seek antibodies: cell
surface and "other" antigens.
For Antibodies to Cell Surface Antigens
A. Suspend 2 x 10' cells in 0.1 ml saline, emulsify in 0.1 ml of complete Freund's adju-
vant, and inject 0.2 ml in the hind foot pads and intraperitoneally.
B. Wait three weeks.
C. Boost animal intravenously with 2 x 10' cells suspended in 0.5 ml saline.
D. Fuse spleen cells three days later.HOW TO MAKE A HYBRIDOMA
For Antibodies to "Other" Antigens
A. Take 0.1 ml of the antigen-containing solution where the antigen concentration is be-
tween 5-100 Ag/0.1 ml and emulsify with 0.1 ml of CFA.
B. Immunize in the hind foot pads and peritoneum.
C. (Optional) Bleed mouse 12 days later and assay serum for antibody activity.
D. Boost with 5-100 jg of antigen IV (IP, if particulate).
E. Fuse spleen cells three days later.
MEDIA, CHEMICALS AND SOLUTIONS
Numerous tissue culture components are needed to facilitate the production of
monoclonal antibodies. A list of the individual components with suggested vendors
is followed by the mixtures made from these chemicals.
Hypoxanthine MW 136.1 (Sigma)
Aminopterin MW 440.4 (Sigma)
Thymidine MW 242.2 (Sigma)
8-Azaguanine MW 152.1 (Sigma)
Polyethylene Glycol 1500 (BDH -from Gallard-Schlesinger Chemical Manufacturing Cor-
poration)
1M HEPES (GIBCO)
200 mM L-Glutamine (Flow)
100 mM Sodium Pyruvate (Flow)
Penicillin-Streptomycin
5000 IU/ml-5000 mcg/ml (Flow)
Antibiotic-Antimycotic
Penicillin 10,000 IU/ml
Streptomycin 10,000 IU/ml
Amphotericin 25 mcg/ml (GIBCO)
NCTC 109 (Microbiological Associates)
RPMI 1640 (GIBCO)
DMEM with 4,500 mg/L glucose (GIBCO)
Serum
All serum is heat inactivated by placing the bottle in a 56°C water bath for 30-45 minutes.
Fetal calf serum which has been screened for supporting the growth of hybrids is used for
the initial stages of hybridoma culture.
"Bobby calf" or calf serum, which is much less expensive than fetal calf serum, is used for
hybrids beyond the 10 ml culture stage and for the maintenance of SP 2 cells.
Concentrations
The concentrations of HAT are from Littlefield's original paper with the exception that we
use 2 x aminopterin. The calculated final molarities of these reagents and 8-azaguanine have
been made assuming that an aliquot of the particular chemical is placed in a total volume of
500 ml-a slightly incorrect assumption as the additives (serum, etc.) result in a final volume
greater than 500 ml.
100 x HT
38.8 mg Thymidine (1.6 x 10-5M)
136.1 mg Hypoxanthine (1.0 x 10-4M)
100 ml d.d. H20 warmed to 70-80°C
Filter sterilize.
Store at -20°C in 5.0 ml aliquots.
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1000 x A
35.2 mg Aminopterin (8 x 10-7)
100 ml d.d. H20
Add IN NaOH dropwise to dissolve.
Bring to 100 ml with d.d. H20.
Filter sterilize.
Store at -20°C in 0.5 ml aliquots.
8-Azaguanine
200 mg Azaguanine (20 ug/ml)
10 ml d.d. H20
Dissolve by adding IN NaOH and bring up to 20 ml with H20.
Filter sterilize.
Store at -20°C in 1 ml aliquots.
50% Polyethylene Glycol 1500
20 gm PEG: autoclave for 30 minutes in a 100 ml bottle.
Add 20 ml DMEM to cooling but molten PEG.
Store at room temperature in 1 ml aliquots (it will become quite alkaline).
Mediumfor SP 2
500 ml RPMI 1640
5 ml HEPES
5 ml L-glutamine
50 ml serum
10 ml pen-strep
1 ml azaguanine
Grow in 5% CO2.
Do not let cell density exceed
7 x 105 cells/ml.*
HTMedium
500 ml DMEM
5 ml HEPES
5 ml L-glutamine
5 ml sodium pyruvate
5 ml HT
50 ml NCTC 109
100 ml fetal calf serum
5 ml antibiotic-antimycotic
Grow in 8% C02.
Beggar's Medium (for stable hybrids)
500 ml RPMI 1640
5 ml HEPES
5 ml L-glutamine
50 ml serum
10 ml pen-strep
Grow in 5%0 C02.
HATMedium
500 ml DMEM
5 ml HEPES
5 ml L-glutamine
5 ml sodium pyruvate
5 ml HT
50 ml NCTC 109
100 ml fetal calf serum
5 ml antibiotic-antimycotic
0.5 ml aminopterin
Grow in 8%o CO2.
FUSION
The actual act of fusing myeloma and spleen cells takes only minutes. While these
minutes are indeed crucial to the success ofmaking hybridomas, planning for the fu-
sion and maintenance of the hybrids requires the utmost diligence.
*If the cells are grown in flasks, an estimate of cell density can be made by viewing the flask on an in-
verted microscope: when the cells are nearly adjacent to one another, the cell density is about 5 x 105
cells/ml, and they should be split. Splitting is done most simply by taking0.5 ml from the mature cultures
and adding to 10 ml of new medium, i.e., 1:20 split.
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Materials
DMEM
PEG
HT medium
HAT medium
60 x 15 mm Petri dishes
Forceps
3 ml syringe
Pipettes (Corning)
15 ml centrifuge tubes
37°C waterbath
Flat bottom microtiter plates (the design ofCOSTAR plates makes them least susceptible to
contamination)
Watch with second hand
Preparation ofSpleen Cells
1. Remove spleen from mouseprimed threeweeks and then boosted three days before the
day of the fusion and place in Petri dish containing 3 ml DMEM.
2. Tease cells from spleen using a forceps and 3 ml syringe.
3. Spin cells at 1,500 RPM for five minutes.
4. Remove supernatant and add DMEM to wash cells. Do cell count at this time. Spin
down cells as above.
Preparation ofSP 2 Cells
1. Plan ahead of time approximately how many SP 2 cells will be needed to do the fu-
sion. (They have a doubling time of 16-20 hours.) Assume that an average spleen
yields 1 x 108 cells. The spleen-to-myeloma cell ratio is 3:1, but any ratio from 1:1 to
10:1 can work.
2. On the day before fusion, transfer the SP 2 cells to media without 8-azaguanine to
deplete any intrecellular pools and to insure log-phase's growth of the myeloma cells
on the day of fusion.
3. On the day of fusion, wash cells with DMEM once and count.
Fusion Procedure
1. Place PEG in CO2 incubator the day before fusion to adjust pH.
2. Warm DMEM and PEG to 37°C in waterbath.
3. Mix the SP 2 cells and the spleen cells together in a 15 ml centrifuge tube and sp'in at
1,500 rpm for 10 minutes.
4. Remove supernatant and leave pellet intact. Do not vortex or tap tube.
5. While holding tube in hand, slowly, over the period of one minute, add 0.8 ml of
warmed PEG to packed pellet using a 1 ml pipette. Mix PEG with pellet by rotating
the pipette tip. Do not draw up into the pipette.
6. Leave tube in hand for 1 minute.
7. Add 1 ml of the warmed DMEM over 1 minute. Tube should still be in hand to keep
the temperature up.
8. Repeat step 7.
9. Add 10 ml of the warmed DMEM over two minutes.
10. Spin for 10 minutes at 1,500 rpm.
11. Remove supernatants and resuspend in HT medium so that the final concentration is
1 x 106 total cells/0.12 ml.
12. Using a sterile 5 ml Corning glass pipette, add two drops/well into a microtiter plate.
Only use the inner 60 wells of the plate. The outer 36 wells can be filled with 200 ml of
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5 ml pipettes delivers about 0.12 ml, which is why this odd figure is used in step 11
rather than 0.1 ml. For every microtiter plate in which the inner 60 wells are used, 7.2
ml of medium can be added, assuming two drops/well (Fig. 3).
Maintaining Newly Fused Cells
1. Call the day of the fusion day 0.
2. On day 1, add one drop of HAT medium to each well.
3. On day 4, aspirate half of the supernatants from each well (a flamed six-inch Pasteur
pipette attached to an aspirator works well) and replace with 2 drops of HAT medium.
4. Repeat step 3 on day 7.
5. After day 7, fusomas may be fed HT medium on a regular basis, every three to five
days.
6. Clones should appear macroscopically between 10 to 20 days (Fig. 4).
SCREENING ASSAYS
The need for a rapid, reproducible, and sensitive screening assay before fusing the
cells cannot be overemphasized. Once the cells have been fused, there is not suffi-
cient time to work out the details of a screening assay. The type of assay needed
depends on the antigen to which antibodies are being produced. Three types of
assays are presented below. The first two are useful for detecting antibodies to cell
surface antigens. In the first assay, target cells are incubated with hybridoma culture
supernatant and antibody from the culture binds the desired cell surface antigen.
This binding is detected by the addition of a radio-labeled second reagent, usually
125I-protein A which binds most classes of mouse immunoglobulin except IgM. Pro-
tein A does not bind most B cells because most B cells bear IgM. If B cells are not
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FIG. 3. Microtiter grid. A chart such as this one is useful for keeping track of clones from
the time of early growth through subcloning.
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FIG. 4. Phase contrast photomicrograph of a typical early hybridoma clone in a microtiter well. Note
the presence of cellular debris, fibroblast-like cells, and portions of two other clones in the field.
Photograph was taken with Kodak plus-X film using a Nikon camera and microscope. x 250.
present in the target population, then I2'l-rabbit anti-mouse Ig should be used in-
stead of protein A so that all mouse antibody classes will be detected. The second
assay is a complement-dependent cytotoxicity assay in which cells are incubated with
hybridoma culture fluid followed by a source of rabbit complement, which leads to
cell lysis as a readout of positive activity. This assay has the advantage over the first
one in that clones secreting IgM antibodies, which are almost invariably cytotoxic,
are detected but the assay is more tedious.
The third assay is a solid-phase sandwich radioimmunoassay which can be used to
detect antibodies to virtually any nominal antigen. The antigen of interest (which
need not be highly purified) is spontaneously bound to plastic 96-well plates by an
electrostatic interaction between plastic and antigen. Culture fluid is then added and
the binding of hybridoma antibody to antigen-coated wells is detected by a labeled
second step reagent such as 125I-protein A or '2II-rabbit anti-mouseimmunoglobulin.
Rabbit anti-mouse Ig is advantageous over protein A because all classes of mouse
antibodies can be detected. An enzyme-linked immunoadsorbent assay (ELISA)
system can be used instead of radio-labeled compounds.
SCREENING ASSAY FOR CELL SURFACE ANTIGENS
Materials
Running buffer -PBS-D + 5Wo fetal calf serum or 0.1 o BSA + 0.1% sodium azide
Blocking buffer- I o BSA in PBS-D + 0.I o sodium azide
Flexible polyvinyl microtiter plates
500 ul Hamilton syringe
2.5 ml Hamilton syringe
Delivery adaptor for Hamilton syringe
l25l-protein A
395Vortex
Refrigerated centrifuge with microtiter carriers
Heat lamp
Radioactive waste disposal
Gamma counter
1. Prepare "blocked" plates by incubating the wells of flexible plates overnight with
blocking buffer. Wash the plates three times with PBS before use.
2. Prepare test cell suspension of 5 x 10' cells/ml in running buffer.
3. Add 50 ul of test hybridoma supernatant to wells of blocked plate.
4. Add 10 ul of spleen cell suspension via Hamilton syringe.
5. Incubate 45 minutes at 4°C.
6. Fill wells with running buffer.
7. Centrifuge at 1,300 rpm for 1.5 minutes at 4°C.
8. Flick supernatant.
9. Fill wells again with running buffer, spin, and flick.
10. Resuspend cells with Vortex.
11. Add 50 ul of 125I-protein A diluted in running buffer via Hamilton syringe. Use20,000
cpm/well.
12. Incubate 45 minutes at 4°C.
13. Repeat step 9 four times.
14. Vortex.
15. Repeat step 9 two more times.
16. Blot dry and dry under heat lamp.
17. Cut out wells and count in gamma counter or perform autoradiography by affixing
X-ray film to bottom of plate. Background counts are typically 100 cpm with positive
wells ranging from 200 to 2,000 cpm, depending upon the antibody and antigen.
CYTOTOXIC ASSAY
Materials
15 ml plastic tubes
Terasaki style test plates
Filter paper strip
100 ul Hamilton syringe
Delivery adaptor for Hamilton syringe
Hank's 199 medium (lOx)
Sodium bicarbonate
Fetal calf serum (FCS)
60 x 15 mm Petri dishes
Ficoll-Hypaque
Centrifuge
Nigrosin (vital dye)
C' (rabbit complement)
Antibody
Prepare medium (A) for cytotoxic test by combining
10 ml Hank's 199 (lOx)
90 ml H20
0.035 g NaHCO3
Prepare medium (B) by combining
10 ml Hank's 199 (Ox)
90 ml H20
0.035 g NaHCO3
5 ml FCS
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1. Cell Separation
a. Place lymph nodes or spleen (depending on experiment) in Petri dish with 2 ml
medium A and tease out cells with two ground glass slides.
b. Transfer cells to 15 ml tube and add 8 ml medium A.
c. Centrifuge at 1,000 rpm for seven minutes.
d. Aspirate supernatant and resuspend cells in 2 ml medium A.
e. Layer cells on 2 ml of Ficoll-Hypaque in 15 ml tube.
f. Centrifuge at 1,500 rpm for 20 minutes.
g. Remove cells from interface, transfer to a 15 ml tube, and add 8 ml medium A.
h. Centrifuge at 1,000 rpm for seven minutes.
i. Wash cells two additional times with 5 ml medium A.
j. Count cells and adjust to 1 x 106 cells/ml.
2. Preparation of Antisera
a. Make up doubling dilutions of hybridoma culture supernatant out to 1/64.
b. Line the inside of microtest plates with filter paper and moisten with medium A. Keep
lid secure to maintain a humidified atmosphere.
c. Transfer antibody to plate using Hamilton syringe with adaptor (i.e., add 2 ul to each
test well).
d. Add medium to remaining wells (controls).
e. Refrigerate plate until ready for test.
3. Addition of Cells
a. Add 2 ul of cells to each well via Hamilton syringe.
b. Incubate 15 minutes at 37°C.
c. Add one drop of cold medium without FCS and let cells settle for 10 minutes in
refrigerator.
d. Flick excess medium from plate (cells will remain on bottom of well).
4. Addition of complement (C')
a. Prepare appropriate complement dilution in medium without FCS.
b. Add 2 ul of C' to test wells via Hamilton syringe.
c. Incubate 30 minutes at 37°C.
5. Addition of Vital Dye
a. Add one drop of cold 0.1Wo Nigrosin to test wells.
b. Incubate plates 10 minutes in refrigerator.
c. Flick plate.
d. Add one drop medium.
e. Count number of live versus dead cells.
SCREENING ASSAY FOR NOMINAL ANTIGENS
Materials
Running buffer-PBS-D
Blocking buffer- 1o BSA in PBS-D + 0.I7o sodium azide
Flexible polyvinyl microtiter plates
500 ul Hamilton syringe
50 ul adaptor for Hamilton syringe
125I protein A or 125I rabbit anti-mouse immunoglobulin
Radioactive waste disposal
Gamma counter
Antigen
1. Prepare a 2 ug/ml solution of antigen in PBS. The exact concentration needed for a
particular antigen will have to be tested for by titration.
2. Add 50 ul of antigen solution to microtiter plate via Hamilton syringe.
3. Incubate overnight at 4°C.
4. Fill wells with running buffer.
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5. Flick supernatant and blot plate dry.
6. Add 50 ul of hybridoma supernatant.
7. Incubate eight hours at 4°C.
8. Fill wells with running buffer.
9. Flick supernatant.
10. Repeat steps 8 and 9.
11. Add 50 ul of 12"I-protein A or anti-Ig in running buffer via Hamilton syringe. Use
20,000 cpm/well.
12. Incubate eight hours at 4°C.
13. Repeat steps 8 and 9 five times.
14. Blot plate dry.
15. Cut out wells and count in gamma counter or perform autoradiography by affixing
X-ray film to bottom of plate.
CLONING AND EXPANSION OF HYBRIDOMAS
Once it has been determined which wells of the original master microtiter plates
contain hybridomas of potential interest, it is imperative that the cells from these
wells be (1) expanded to 1 ml cultures and (2) subcloned immediately. The reasons
are manyfold: (1) expansion will place the hybrids in multiple places insuring against
the potential loss secondary to contamination and other accidents, (2) the hybrids
are very unstable at this juncture so that the appearance of one colony of cells does
not necessarily mean that all of the cells are producing antibody and non-producers
could easily overgrow the producers, and (3) multiple activities could be present in a
single well and cloning is necessary to examine this possibility.
A "feeder" layer is used at this early stage of expansion and cloning. BALB/c
thymocytes are sufficient feeders for any fusion because the myeloma line SP 2/0 is
derived from a BALB/c hybridoma. There are only two occasions when a feeder
layer is necessary. One is in the actual cloning process by limiting dilution or solid
agar (the latter is easier); the other, when the 0.2 ml master well is expanded to 1 ml
culture. Expansion of the subclones from limiting dilution or agar cloning does not
require feeder cells nor does expansion from 1 ml to a 10 ml culture.
In the sections which follow, "HT" medium is often used. It should be noted that
hypoxanthine and thymidine are not necessary for the growth ofhybrids by this time
and that it is simpler to add HT to the media to avoid any confusion that may arise
between improperly labeled bottles.
EXPANSION OF ORIGINAL POSITIVE 0.2 ML MASTER WELL
(UNCLONED COLONY)
Materials
BALB/c mice
PBS-D
Ground glass slides
HT medium
1 ml multiwell plates
Pipette tips
Plasticware
1. Prepare BALB/c thymocytes suspension in PBS-D by mincing the thymus between
two ground glass slides.
2. Wash one time with PBS-D.
3. Resuspend in 10 ml HT medium/thymus.
4. Aliquot into 1 ml multiwells.
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5. Transfer the entire contents of the 0.2 ml master well to the 1 ml culture.
6. Remove 0.2 ml from the 1 ml culture and replace in the master well. (This procedure is
a safeguard in the rare event the 1 ml culture fails to grow.)
7. Three to six days later cells will cover the multiwell and media will be yellow. It should
be tested for activity.
8. If it is still active, expand this uncloned colony to a 10 ml flask.
9. Supernatant from the 10 ml flask should be saved and the cells frozen in the evient the
concurrent cloning procedure fails and must be repeated.
CLONING ON HARD AGAR (0.5%)
A. Preparation ofAgar
Materials
Difco agar (Bacto-agar)
PBS-D
60 x mm tissue culture dishes
100 ml bottles
Autoclave
HT medium
Pipettes
1. Weigh out 0.5 gm agar.
2. Place in 100 ml bottle.
3. Add 7.5 ml PBS-D.
4. Autoclave for 30 minutes.
5. While the agar is still molten, quickly add 94 ml HT media warmed to 37°C, and mix
vigorously with a pipette.
6. Rapidly add 5 ml to each of 20 dishes.
7. Let agar harden in the hood for 45 minutes.
8. Place dishes in 8%o CO2 incubator to adjust pH.
B. Cloning on Agar
The idea is to have four dishes/colony (for safety reasons), two with 1,000 col-
onies/dish and two with 200 colonies/dish (to insure a "pluckable" number of
clones).
The hybrid cells should be accurately counted from 20 ul of the original master
well mixed with 20 ul of a vital dye (e.g., Trypan Blue) or 50 ul of the 1 ml uncloned
culture mixed with 50 ul of a vital dye. Typically, there will be about 1 x 105 live
hybrids/master well.
Materials
Agar dishes
BALB/c thymocytes-one thymus/five agar dishes
Pasteur pipettes (small variety)
1 ml multiwell plates
Microtiter plates
HT medium
Beggar's medium
1. Mix thymocytes and hybrid cells such that 1/5 thymus and 200 or 1,000 hybrid cells
are suspended in 50-75 ul of HT medium.
2. Add suspension to agar dishes.
3. Spread the suspension (it will cover the dish) with an alcohol-flamed curved glass rod.
4. Place in 8W7o CO2 incubator.
5. Check two days later for gross contamination.
3996. Check by day 7 for small visible clones.
7. Usually within two weeks, and sometimes by day 7, pluck at least 20 macroscopic
clones per hybrid with a Pasteur pipette and release the agar plug into a microtiter well
containing 200 ul HT medium (no feeder cells needed).
8. Screen the supernatents when yellow.
9. Expand three positive clones to 1 ml cultures (no feeder cells needed) and test the
supernatants when ready.
10. Expand one of the 1 ml cultures to 10 ml cultures and test when ready.
11. Any positive clone at this point is stable and one 10 ml flash should be split 1:20 in
Beggar's medium for the production of useful quantities of supernatant and freezing
the hybridoma line. Cells should also be grown to prepare high-titered ascites fluid.
CLONING BY LIMITING DILUTION
The idea behind limiting dilution is to obtain a series of wells with one hybrid
clone per well. Generally this goal is achieved by plating a large number ofmicrotiter
wells with dilutions of 5, 1, and "0.5" hybrid cells/well and testing supernatants
from the population of wells that have growth in at most 37 percent of the wells.
This technique assures monoclonal growth in these wells on the basis of the Poisson
distribution. We have found that any well with "5" hybrid cells to begin with always
has growth and therefore, rather than plate wells at three dilutions, we put one
cell/well and 0.5 cell/well and test the ones with visual monoclonal growth.
Materials
BALB/c thymocytes-one thymus/two hybrids
Microtiter plates
HT medium
Pipettes
1. Prepare thymocytes feeder cells and mix with hybrid cells such that 1/2 thymus and 60
hybrid cells are suspended in 7.5 ml HT medium (30 for 0.5 cell/well).
2. Add two drops from a 5 ml pipette to the inner 60 wells of a microtiter plate. (This
procedure will use all 7.5 ml.)
3. Place in 8%7o CO2 incubator.
4. Examine for growth four days later.
5. Add 1-2 drops HT medium/well.
6. Test at least 20 supernatants when yellow.
7. Proceed to step 9 of B, Cloning on Agar.
FREEZING OF HYBRIDOMA LINES
In general, freeze at least 106 cells/vial. An appropriate number of cells will be
frozen if, for every 10 ml of culture, one vial of cells is stored (approximately
3 x 106 cells during log phase growth).
Materials
Freezing vials
Dimethyl sulfoxide (DMSO)
Serum
1. Prepare 9007o serum 10% DMSO by adding DMSO (assume it is sterile) to serum and
mixing.
2. Spin hybrid cells.
3. Resuspend cells in FCS-DMSO (1 ml/10 ml culture).
4. Place in freezer vial.
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5. Freeze slowly overnight in styrofoam container in liquid N2 freezer or -70°C freezer.
6. Remove styrofoam insulator the next day and place in liquid N2 freezer.
Thawing Cells
1. Warm vial quickly in 37°C waterbath.
2. Immediately upon thawing pour over 10 ml of PBS already in centrifuge tube.
3. Spin to dilute the DMSO.
4. Resuspend in 10 ml warm HT medium.
5. Place in incubator.
6. Check for growth the next day.
7. Expand in Beggar's medium.
PREPARATION OF HIGH TITERED ASCITES
MONOCLONAL ANTIBODY
Materials
BALB/c or F, mice to match MHC haplotype of BALB/c and fusion partner (Irradiated
BALB/c or nude mice may also work.)
Pristane 2,6,10,14-tetramethylpentadecane (Aldrich)
Hybridoma
Syringe/needles
1. Prime mice with 0.5 ml Pristane IP at least five days before injecting hybrid cells. (Ifa
vital culture is contaminated, we suggest priming a mouse and injecting the cells the
same day in the hope that the mouse will eliminate the infection from the cell line and
not kill the hybrids, allowing them to be recovered in a sterile state from the mouse.)
2. Inject 1-5 x 101 hybrids IP in ½ ml saline.
3. Tap the mice when ascites develops (one to three weeks), usually every other day until
the mice succumb.
4. Spin or filter ascites fluid.
5. Precipitate the gamma globulin fraction of the ascites with at least one precipitation
using 450'o saturated ammonium sulfate. Sodium sulfate seems to destroy monoclonal
antibody activity and should not be used.
6. Spin at 3,000 rpm for 15 minutes.
7. Resuspend and dialyze the antibody against a desired buffer at 4°C.
8. Store sterilely or with0.1%No azide in the refrigerator or as aliquots in the freezer. Avoid
freezing and thawing.
9. To obtain cleaner samples of monoclonal antibody, the antibody can be selectively
passed over or eluted from a protein A-sepharose column or subjected to other affinity
purification procedures.
DIFFICULTIES IN THE PRODUCTION OF HYBRIDOMAS
It should be apparent from reading this guide that tedious work is a requirement
for the successful production of monoclonal antibodies. In addition, there are three
major difficulties associated with making hybridomas. First, as with any tissue
culture technique, the fear of infection is ever present. Antibiotics combined with
good sterile technique are usually successful at preventing bacterial contamination.
Molds are more difficult to prevent. Antimycotics are usually successful at delaying
but not preventing this kind of contamination. Contaminated wells appear most
commonly in the outer wells of the microtiter plates which suggests spread from the
incubator, and it is for this reason that the outermost wells of the plate should not
contain medium. If a plate is found to have contaminated wells, it is usually best to
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discard the plate. If there is a pressing reason to maintain the particular plate, the
contents of as many wells as possible should be replaced with a saturated copper
sulfate solution.
The second problem concerns the sluggish growth or lack of growth of visible
clones after a fusion. How is it possible that healthy-appearing tumor cells cease
dividing? A clear answer is not available but presumably various factors produced
by cells in the original spleen cell population have the ability to suppress hybridoma
growth. Transferring the cells to a new microtiter plate usually solves this problem
as the suppressive cells appear to be left behind in the master well. An extension of
this problem concerns the slow or unsuccessful growth of cells after splitting or
changing from HT to Beggar's medium. If cells are split in too dilute a fashion,
growth can generally be salvaged by centrifugation ofthe cells and resuspension in a
smaller volume of medium. Sometimes a cell line will begin to die when transferred
from HT to Beggar's medium. In this case it is necessary to place the cells into HT
medium again for a few days and test to see if the cells that grow out are capable of
being sustained in Beggar's-they usually do well the second time.
The third problem is the loss of antibody production by hybridomas. This
phenomenon is common in the early stages ofgrowth as cell hybrids have a tendency
to lose chromosomes. Often 50 percent ofthe original positive wells will be lost. Early
cloning is essential to obtain relatively stable hybrids and it is not unreasonable to
suggest that a particular line be subcloned three times before it is considered stable.
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